Skip to content

Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)

Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03366506
Acronym
EpidALS
Enrollment
2000
Registered
2017-12-08
Start date
2009-03-09
Completion date
2050-01-31
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALS

Brief summary

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:- 1. Differences between ethnic subgroups 2. Differences between immigrant and native-born populations 3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

Detailed description

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:- 1. Differences between ethnic subgroups 2. Differences between immigrant and native-born populations 3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors. The clinical features will include pattern of onset, details of full clinical exam ( including ALSFRS-R score, power, reflexes, and other signs of upper or lower-motor neuron dysfunction. Correlations between different clinical parameters themselves will be made, as well as correlation between clinical parameters and other epidemiological factors.

Interventions

OTHERObservation

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 120 Years

Inclusion criteria

\- Suspected, possible, probable ,definite ALS

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Progression rateup to 10 yearsProgression of ALSFRS-R score over time

Secondary

MeasureTime frameDescription
Appearance of clinical features of UMN or LMN dysfunction10 yearsAppearance of clinical features of UMN or LMN dysfunction over time

Countries

Israel

Contacts

Primary ContactMarc Gotkine, MBBS
marc@gotkine.com+972507874692

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026